Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical "Soft" JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
Stock Information for Aclaris Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.